TickerFacts.

Company research / TEVA

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Build a valuation ↗↓ Download CSV

CIK 0000818686 · NYSE · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated L3
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, TEVA PHARMACEUTICAL INDUSTRIES LTD reported revenue of $17.26B. Revenue grew 4.3% from the prior annual period.

Key ratios (year ended 2025-12-31)

51.8%
Gross margin
12.5%
Operating margin
8.2%
Net margin
17.8%
Return on year-end equity
4.3%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: 8-K · 2026-09-03

Headquarters locality: Ramat HaHayal / Tel Aviv · View on map

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. A dash means a matching observation is unavailable.

Period ended2025-12-312024-12-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302021-12-31
Revenue$17.26B$16.54B$15.85B———$14.93B——$15.88B
Cost of Revenue$8.32B$8.48B$8.20B———$7.95B——$8.28B
Gross Profit$8.94B$8.06B$7.64B———$6.97B——$7.59B
Operating Income$2.16B-$303.00M$433.00M———-$2.20B——$1.72B
Net Income$1.41B-$1.64B-$559.00M———-$2.45B——$417.00M
EPS (Diluted)$1.21$-1.45$-0.50———$-2.20——$0.38
Total Assets$40.75B$39.33B$43.48B$42.09B$43.10B$43.46B$44.01B$44.25B$45.93B$47.67B
Total Liabilities$32.83B$33.61B$35.35B$34.71B$35.51B$34.96B$35.41B$34.75B$36.12B$36.42B
Shareholders' Equity$7.91B$5.38B$8.13B$7.39B$7.59B$8.50B$8.60B$9.51B$9.81B$11.24B
Cash & Equivalents$3.56B$3.30B$3.23B———$2.80B——$2.17B
Operating Cash Flow$1.65B$1.25B$1.37B———$1.59B——$798.00M
Capital Expenditures$501.00M$498.00M$526.00M———$548.00M——$562.00M
Weighted Average Diluted Shares1.16B1.13B1.12B———1.11B——1.11B
EPS (Basic)$1.23$-1.45$-0.50———$-2.20——$0.38